Natco Pharma Receives Tentative US FDA Approval for Olaparib Tablets
Natco Pharma received tentative U.S. FDA approval for Olaparib 100 mg and 150 mg tablets. Natco will manufacture the drug, with Alembic Pharmaceuticals handling U.S. distribution. Olaparib tablets had estimated U.S. sales of USD 1.4 billion for the 12 months ending March 2026.
The tentative approval is a positive step, but the ongoing litigation and the fact that it's not final approval moderate the immediate impact. However, the product's high market sales indicate potential for significant future revenue.
The tentative approval from the U.S. FDA for Olaparib tablets is a positive development for Natco Pharma, indicating progress in launching a product with significant market potential.
Natco Pharma Limited has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for Olaparib, 100 mg, and 150 mg tablets. These tablets are bioequivalent to the reference listed drug, Lynparza® tablets, for the indication in the approved labeling.
Natco will be responsible for manufacturing the Olaparib tablets, while its partner, Alembic Pharmaceuticals Limited, will distribute the product in the U.S. The company noted that the Paragraph IV litigation concerning this product is ongoing. The estimated sales for Olaparib tablets in the U.S. were approximately USD 1.4 billion for the 12 months ending March 2026, according to industry sales data.
Natco Pharma Limited, headquartered in Hyderabad, India, is a research and development-oriented pharmaceutical company specializing in generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products. The company has a significant presence in the oncology market and focuses on limited competition molecules in the U.S. It operates nine manufacturing sites and two R&D facilities in India, with several manufacturing facilities approved by international regulatory authorities.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.